|Bid||0.9600 x 800|
|Ask||1.0400 x 900|
|Day's Range||0.9600 - 1.0500|
|52 Week Range||0.7740 - 3.7500|
|Beta (3Y Monthly)||1.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 22, 2018 - Feb 26, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
Bioblast Pharma Ltd. (ORPN) (“Bioblast” or the “Company”), a clinical-stage, orphan disease-focused biotechnology company, announced today that it received a written notification from the Listing Qualifications Department of The Nasdaq Capital Market (“Nasdaq”) notifying the Company that Nasdaq has determined that Bioblast’s stockholders’ equity does not comply with the minimum $2,500,000 stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1).
NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.
Heading into the holiday week, a number of healthcare names are taking hold of a bull market in healthcare stocks. HealthVue currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.
Enlivex is developing a novel immunotherapy with a unique mode of action targeting clinical indications defined as “life-threatening, unmet medical need,” such as preventing or treating complications associated with bone-marrow transplantations, sepsis – which is the third-leading cause of mortality in the U.S. after cardiovascular and cancer diseases, as well as effective treatment of solid tumors via immune checkpoint reprogramming, increasing the efficacy of CAR-T, TCR and other anti-cancer therapies. Phase IIa clinical trial for the prevention of GvHD in matched-donor population successfully completed. Initiation of Phase II clinical trial in sepsis expected in Q2-2019, and initiation of a Phase II clinical trial for treatment of steroid-refractory GvHD patients and a Phase II/III clinical trial for preventing GvHD in bone marrow transplantations are expected in Q4-2019.
Today, I will be analyzing Bioblast Pharma Ltd’s (NASDAQ:ORPN) recent ownership structure, an important but not-so-popular subject among individual investors. When it comes to ownership structure of a company, theRead More...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! athenahealth, Inc (NASDAQ: ATHN ) stock was trading ...
If you are looking to invest in Bioblast Pharma Ltd’s (NASDAQ:ORPN), or currently own the stock, then you need to understand its beta in order to understand how it canRead More...
I am going to take a deep dive into Bioblast Pharma Ltd’s (NASDAQ:ORPN) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structureRead More...